Skip to site menu Skip to page content
Ypsomed
Go back

Sustainable GLP-1 Drug Delivery: Future-Proofing Therapy Administration for Obesity and Beyond

Lorenzo Biasio and Gloria Skibba, both at Ypsomed, discuss the integration of the company’s Net Zero Program into its self-injection platforms and explain how YpsoMate 1 and 2.25 mL autoinjectors have been redesigned to achieve a lower carbon footprint.
Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content